Catalog No.
YHE41901
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Met1-Val317
Predicted molecular weight
34.9 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P43358
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Cancer/testis antigen 1.4, MAGEA4, MAGE4, CT1.4, Melanoma-associated antigen 4, MAGE-X2 antigen, MAGE-41 antigen, MAGE-4 antigen
Expression of Cancer-Testis Antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China., PMID:40152485
Mapping MAGE-A4 expression in solid cancers for targeted therapies., PMID:40151801
Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy., PMID:40122967
Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy., PMID:39970827
Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies., PMID:39954349
Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma., PMID:39949781
MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation., PMID:39937892
Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy., PMID:39905312
A panel of cancer testis antigens in squamous cell carcinoma of the lung, head and neck, and esophagus: implication for biomarkers and therapeutic targets., PMID:39864021
Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis., PMID:39704015
MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity., PMID:39572159
Afamitresgene Autoleucel: First Approval., PMID:39404764
Long non-coding RNA MAGEA4-AS1 binding to p53 enhances MK2 signaling pathway and promotes the proliferation and metastasis of oral squamous cell carcinoma., PMID:39249547
Long-term culture of human Sertoli cells from adult Klinefelter patients as a first step to develop new tools for unravelling the testicular physiopathology., PMID:39237101
Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics., PMID:39224047
Potentially actionable targets in synovial sarcoma: A tissue microarray study., PMID:39029378
Crystal structure of MAGEA4 MHD-RAD18 R6BD reveals a flipped binding mode compared to AlphaFold2 prediction., PMID:38907034
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients., PMID:38872830
Novel mutation leading to splice donor loss in a conserved site of DMD gene causes Duchenne muscular dystrophy with cryptorchidism., PMID:38621993
Cancer testis antigen MAGEA3 in serum and serum-derived exosomes serves as a promising biomarker in lung adenocarcinoma., PMID:38555374
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial., PMID:38554725
Structural basis for RAD18 regulation by MAGEA4 and its implications for RING ubiquitin ligase binding by MAGE family proteins., PMID:38448672
Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex., PMID:38243600
Autologous engineered T cell receptor therapy in advanced cancer., PMID:38114231
Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4., PMID:37894816
Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma., PMID:37866309
CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model., PMID:37857018
Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets., PMID:37610673
TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach., PMID:37535601
Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer., PMID:37341056
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report., PMID:37325860
Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors., PMID:37266606
Tyrosinase-Catalyzed Peptide Macrocyclization for mRNA Display., PMID:37155687
Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM., PMID:37100770
Granulocyte-colony stimulating factor does not prevent in vitro cisplatin-induced germ cell reduction in immature human and mouse testis., PMID:36922758
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α., PMID:36826388
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial., PMID:36624315
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer., PMID:36594104
Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients., PMID:36527482
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial., PMID:36375974
Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy., PMID:35872653
PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report., PMID:35839046
The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook., PMID:35830892
Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma., PMID:35736245
Sertoli and Germ Cells Within Atrophic Seminiferous Tubules of Men With Non-Obstructive Azoospermia., PMID:35721721
Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics., PMID:35651938
Discovery and Structural Basis of the Selectivity of Potent Cyclic Peptide Inhibitors of MAGE-A4., PMID:35522528
Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas., PMID:35448937
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer., PMID:35135489
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer., PMID:35086946
For research use only. Not for human or drug use.
